ClinicalTrials.gg

Program

mivelsiran

Also written as “ALN-APP” and “Mivelsiran”.

Its studies are mostly in Cerebral Amyloid Angiopathy · Alzheimer Disease · Down Syndrome, led by Alnylam Pharmaceuticals.

Furthest: phase 2, since Apr 19, 20243 company-led studies, 3 open or runningNext primary completion: Aug 9, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alnylam Pharmaceuticals33 open or runningphase 2since Apr 19, 2024Jan 30, 2022Aug 9, 2027phase 2 · NCT06393712

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 30, 2022First study: phase 1 study in Alzheimer DiseaseFirst studyNCT05231785 · 60 planned · United States, Canada, Netherlands and more
  2. Apr 19, 2024Phase 2 study in Cerebral Amyloid AngiopathyNCT06393712 · 210 enrolled · United States, Australia, Canada and more
  3. Jun 4, 2026Phase 2 study in Down SyndromeNCT07636811 · 58 planned · United States, Spain

Ahead

  1. Aug 9, 2027Primary completion: phase 2 study in Cerebral Amyloid AngiopathyNCT06393712
  2. Jan 11, 2029Primary completion: phase 1 study in Alzheimer DiseaseNCT05231785
  3. May 18, 2030Primary completion: phase 2 study in Down SyndromeNCT07636811

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07636811Down Syndrome · United States, Spain2RecruitingMay 18, 203058
NCT06393712Cerebral Amyloid Angiopathy · United States, Australia, Canada and more2Active, not recruitingAug 9, 2027210
NCT05231785Alzheimer Disease · United States, Canada, Netherlands and more1RecruitingJan 11, 202960

How it is read

Names in the registry

  • “ALN-APP”, 2 entries
  • “Mivelsiran”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.